Skip to main content
Journal cover image

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Publication ,  Conference
White, D; LeBlanc, R; Venner, C; Bahlis, NJ; Lentzsch, S; Gasparetto, CJ; Chen, C; Lipe, B; Sutherland, H; Tuchman, S; Baljevic, M; Kotb, R ...
Published in: Clinical Lymphoma Myeloma and Leukemia
October 2019

Duke Scholars

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

October 2019

Volume

19

Issue

10

Start / End Page

e55 / e55

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
White, D., LeBlanc, R., Venner, C., Bahlis, N. J., Lentzsch, S., Gasparetto, C. J., … Schiller, G. J. (2019). Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). In Clinical Lymphoma Myeloma and Leukemia (Vol. 19, pp. e55–e55). Elsevier BV. https://doi.org/10.1016/j.clml.2019.09.084
White, Darrell, Richard LeBlanc, Chritopher Venner, Nizar J. Bahlis, Suzanne Lentzsch, Cristina J. Gasparetto, Christine Chen, et al. “Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).” In Clinical Lymphoma Myeloma and Leukemia, 19:e55–e55. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.084.
White D, LeBlanc R, Venner C, Bahlis NJ, Lentzsch S, Gasparetto CJ, et al. Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. e55–e55.
White, Darrell, et al. “Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).” Clinical Lymphoma Myeloma and Leukemia, vol. 19, no. 10, Elsevier BV, 2019, pp. e55–e55. Crossref, doi:10.1016/j.clml.2019.09.084.
White D, LeBlanc R, Venner C, Bahlis NJ, Lentzsch S, Gasparetto CJ, Chen C, Lipe B, Sutherland H, Tuchman S, Baljevic M, Kotb R, Sebag M, Callander N, Bensinger W, Kai K, Liu J, Sheehan H, Estepan DN, Shah J, Schiller GJ. Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. e55–e55.
Journal cover image

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

October 2019

Volume

19

Issue

10

Start / End Page

e55 / e55

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences